FRI0220 Allogeneic Mesenchymal Precursor Cells (MPCS): A Novel Approach to Treating Biologic Refractory Rheumatoid Arthritis

doi 10.1136/annrheumdis-2017-eular.1106
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Biologic Refractory Disease in Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2018English

Biologic Treatments for Rheumatoid Arthritis

Trends in Urology & Men's Health
2019English

A Systems Approach to Rheumatoid Arthritis

PLoS ONE
Multidisciplinary
2012English

Allogeneic Mesenchymal Stem Cell Therapy: A Regenerative Medicine Approach to Geroscience

Aging Medicine
AgingGerontologyGeriatrics
2019English

SAT0200 Biologic Therapy Retention in Rheumatoid Arthritis (RA) Patients (PTS) According to the Moscow Arthritis Registry (MAR)

2017English

A Rational Approach to the Treatment of Rheumatoid Arthritis: Introduction

Cleveland Clinic Journal of Medicine
Medicine
1957English

AB0432 Biologic Dmards Treatment Retention in Patients With Rheumatoid Arthritis According to the Moscow Arthritis Registry (MERA)

2018English

Factors Determining Long-Term Success of Biologic Therapy in Rheumatoid Arthritis

Modern Rheumatology Journal
2015English

Biologic Monotherapy in the Biologic Naïve Patient With Rheumatoid Arthritis (RA): Results From an Observational Study

Rheumatology International
RheumatologyAllergyImmunology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy